Literature DB >> 18206543

Molecular cytogenetic findings in a three-way novel variant of t(1;8;21)(p35;q22;q22): a unique relocation of the AML1/ETO fusion gene 1p35 in AML-M2.

Firoz Ahmad1, Prajakta Kokate, Pratiksha Chheda, Rupa Dalvi, Bibhu Ranjan Das, Swarna Mandava.   

Abstract

Acute myeloid leukemia (AML) is a malignant neoplasm of hematopoietic stem cells characterized by an abnormal proliferation of myeloid precursors, a reduced rate of apoptosis, and an arrest in cellular differentiation. The present report deals with the results of hematologic, immunophenotypic, cytogenetic, fluorescence in situ hybridization (FISH), and molecular analyses of a 53-year-old female patient diagnosed with AML-M2. Cytogenetic and FISH analysis revealed a complex translocation involving three chromosomes showing t(1;8;21)(p35;q22;q22). The observation of breakpoints at 8q22 and 21q22 suggests a rearrangement of the ETO and AML1 genes, respectively. Using a dual-color FISH test with ETO and AML1 probes, an AML1/ETO fusion signal on the derivative 1p35 instead of der(8) was demonstrated. To the best of our knowledge, this is the first report about the relocation of the AML1/ETO fusion gene to the 1p35 rather than der(8), suggesting the presence of a novel variant of t(8;21)(q22;q22) in the observed patient.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18206543     DOI: 10.1016/j.cancergencyto.2007.10.005

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  2 in total

Review 1.  Advances in molecular genetics and treatment of core-binding factor acute myeloid leukemia.

Authors:  Krzysztof Mrózek; Guido Marcucci; Peter Paschka; Clara D Bloomfield
Journal:  Curr Opin Oncol       Date:  2008-11       Impact factor: 3.645

2.  Clinical, Cytogenetic, and Molecular Findings in Two Cases of Variant t(8;21) Acute Myeloid Leukemia (AML).

Authors:  Lindsay Wilde; Jillian Cooper; Zi-Xuan Wang; Jinglan Liu
Journal:  Front Oncol       Date:  2019-10-04       Impact factor: 6.244

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.